21 CARDIOVASCULAR RISK AMELIORATION BY METFORMIN-DIET IN POLYCYSTIC OVARY SYNDROME: REDUCTION OF WEIGHT, TRIGLYCERIDES, LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND BLOOD PRESSURE, ELEVATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL. (1st March 2005)

• Record Type: Journal Article
• Authors: Haque, M.; Glueck, C. J.; Goldenberg, N.; Wang, P.
• Is Part Of: Journal of investigative medicine. Volume 53:Number 2(2005)
• Page Start: S390
• Page End: S390
• Publication Date: 2005-03-01
• Subjects: Clinical medicine -- Periodicals; Medicine -- Research -- Periodicals; Medicine; Research -- United States; Clinical medicine; Medicine -- Research; Periodicals; 616.075
• DOI: 10.2310/6650.2005.00205.20
• Languages: English
• ISSNs: 1081-5589

Abstract

Abstract : In 791 women with polycystic ovary syndrome (PCOS), we assessed the success of metformin-diet (MET-D) in reducing weight, triglycerides (TG), LDL cholesterol (LDLC), and blood pressure (SBP, DBP), while elevating HDL cholesterol (HDLC). At pre-treatment (pre-Rx) entry in the 791 women, median weight was 95 kg, with 15% overweight (BMI>25<30), 46% obese (BMI 30-40), and 29% severely obese (BMI ≥ 40). Median pre-Rx TG was 108 mg/dL (30% ≥ 150 mg/dL), LDLC 116 mg/dL (32% ≥ 130 mg/dL), HDLC 46 mg/dL (62%<50 mg/dL), SBP 124 mm Hg (37% ≥ 130 mm Hg), and DBP was 80 mm Hg (30% ≥ 85 mm Hg). Women with BMI<25 or ≥ 25 kg/m2 were given a 2000 or 1500 calorie/day, high protein (26% of calories), low carbohydrate (44%) diet. Metformin was targeted to 2500 mg/day. On MET-D, change in weight was positively associated with change in TG (r = .23, p<.0001), LDLC (r = .11, p = .004), SBP (r = .21, p<.0001), and DBP (r = .17, p = .0003), and was inversely associated with change in HDLC (r = -.10, p = .007). In 102 women (age 30 ± 9 years) on MET-D for 12-18 months (median 14.5), median weight reduction was 5 kg (5%), p <.0001, and median LDLC reduction 6 mg/dL (4%), p = .04. Weight reduction was<5% in 50% of these 102 women, 5-10% in 25%, 10-15% in 13%, and ≥ 15% in 13%. In 65 women (age 31 ± 9 years) on MET-D for 18-24 months (median 21 months), median weight reduction was 6 kg (6%), p<.0001, TG fell 17 mg/dL (19%), p = .045, and HDLC rose 2 mg/dL (6%), p = .002. Weight reduction was<5% in 46% of these 65 women, 5-10% in 26%, 10-15% in 14%, and ≥ 15% in 14%. In 210 women (age 31 ± 9 years) on MET-D for>24 months (median 40), median weight reduction was 5 kg (5%), p<.0001, HDLC rose 4 mg/dL (8%), p<.0001, and LDLC fell 9 mg/dL (7%), p = .0004. Weight reduction was<5% in 48% of these 210 women, 5-10% in 23%, 10-15% in 15%, and ≥ 15% in 15%. In these 210 women, of 108 with HDLC<50 mg/dL pre-Rx, 38 (35%) had HDLC on MET-D>50 mg/dL (p = .002), and of 64 with LDLC ≥ 130 mg/dL pre-Rx, 41 (64%) had LDLC on MET-D<130 mg/dL, p <.0001. In PCOS, where 75% of women are obese or severely obese, and where obesity is often accompanied by high TG, LDLC, and low HDLC, MET-D is very effective in reducing weight, TG, LDLC, and raising HDLC.